Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125)

Ken‐ichi Kusakabe(Futaba (Japan)), Yusuke Nakamura(Rissho University), Yataro Daigo(The University of Tokyo), Yoshio Hato(Futaba (Japan)), Yuji Sato, Masayo Higaki(Shiga University of Medical Science), Motofumi Iguchi(Futaba (Japan)), Nobuyuki Ide(Futaba (Japan)), Hiroshi Hashizume(Futaba (Japan)), Shingo Sakamoto(Shiga University of Medical Science), Kazuya Yasuo(Shiga University of Medical Science), Yasuto Kido(Shiga University of Medical Science), Yuki Tachibana(Futaba (Japan)), Hidenori Yoshizawa(Futaba (Japan)), Kazuo Ueda(Futaba (Japan)), Keiji Dohi(Futaba (Japan)), Itoh Takeshi(Futaba (Japan)), Takayuki Kanazawa(Futaba (Japan)), Takahiko Yamamoto(Shiga University of Medical Science), Kenichi Higashino(Shiga University of Medical Science), Yoshiyasu Baba(Futaba (Japan)), Y. Okano(Shiga University of Medical Science), Yukichi Ishioka(Futaba (Japan)), Makiko Inoue(Howard Hughes Medical Institute), Takeshi Shiota(Futaba (Japan)), Hitoshi Murai(Futaba (Japan)), Masahiro Maeda(Shiga University of Medical Science)
Journal of Medicinal Chemistry
May 2, 2013
Cited by 47


Related Papers